225 related articles for article (PubMed ID: 17488727)
1. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3.
Haacke A; Hartl FU; Breuer P
J Biol Chem; 2007 Jun; 282(26):18851-6. PubMed ID: 17488727
[TBL] [Abstract][Full Text] [Related]
2. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
[TBL] [Abstract][Full Text] [Related]
4. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.
Simões AT; Gonçalves N; Koeppen A; Déglon N; Kügler S; Duarte CB; Pereira de Almeida L
Brain; 2012 Aug; 135(Pt 8):2428-39. PubMed ID: 22843411
[TBL] [Abstract][Full Text] [Related]
5. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
6. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
7. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
[TBL] [Abstract][Full Text] [Related]
8. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
Koch P; Breuer P; Peitz M; Jungverdorben J; Kesavan J; Poppe D; Doerr J; Ladewig J; Mertens J; Tüting T; Hoffmann P; Klockgether T; Evert BO; Wüllner U; Brüstle O
Nature; 2011 Nov; 480(7378):543-6. PubMed ID: 22113611
[TBL] [Abstract][Full Text] [Related]
9. A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3.
Weber JJ; Golla M; Guaitoli G; Wanichawan P; Hayer SN; Hauser S; Krahl AC; Nagel M; Samer S; Aronica E; Carlson CR; Schöls L; Riess O; Gloeckner CJ; Nguyen HP; Hübener-Schmid J
Brain; 2017 May; 140(5):1280-1299. PubMed ID: 28334907
[TBL] [Abstract][Full Text] [Related]
10. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation.
Perez MK; Paulson HL; Pendse SJ; Saionz SJ; Bonini NM; Pittman RN
J Cell Biol; 1998 Dec; 143(6):1457-70. PubMed ID: 9852144
[TBL] [Abstract][Full Text] [Related]
11. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
12. Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control.
Breuer P; Haacke A; Evert BO; Wüllner U
J Biol Chem; 2010 Feb; 285(9):6532-7. PubMed ID: 20064935
[TBL] [Abstract][Full Text] [Related]
13. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
14. Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.
Watchon M; Yuan KC; Mackovski N; Svahn AJ; Cole NJ; Goldsbury C; Rinkwitz S; Becker TS; Nicholson GA; Laird AS
J Neurosci; 2017 Aug; 37(32):7782-7794. PubMed ID: 28687604
[TBL] [Abstract][Full Text] [Related]
15. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
16. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
17. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
18. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3.
Mueller T; Breuer P; Schmitt I; Walter J; Evert BO; Wüllner U
Hum Mol Genet; 2009 Sep; 18(17):3334-43. PubMed ID: 19542537
[TBL] [Abstract][Full Text] [Related]
19. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
[TBL] [Abstract][Full Text] [Related]
20. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease.
Simões AT; Gonçalves N; Nobre RJ; Duarte CB; Pereira de Almeida L
Hum Mol Genet; 2014 Sep; 23(18):4932-44. PubMed ID: 24817574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
